



## Pharmacy and Therapeutics Advisory Forum

Hilton Garden Inn  
9850 Park Plaza Ave  
Louisville, KY 40241

February 18, 2019  
8:30 AM – 10:00 AM

### Agenda

- I. Call to Order – WellCare Introductions & Announcements
- II. Old Business – Updates from November 27, 2018 P&T Meeting
- III. New Business
  - a. Drug Class Reviews

Drug Class
Corticosteroids
Androgen-anabolic
Estrogens
Contraceptives
Progestins
Antidiabetics, Oral
Antidiabetics, Inj
Thyroid
Oxytocics
Misc. Endocrine
Cardiotonics
Antianginal Agents
Beta blockers
Calcium Blockers
Antiarrhythmics
Antihypertensives
Diuretics
Pressors



## Pharmacy and Therapeutics Advisory Forum

Antihyperlipidemics
Misc. cardiovascular
Hematopoietic Agents
Anticoagulants
Hemostatics
Misc. hematological

**b. Speaker Drug Reviews** (\*Requests to present must be submitted prior to meeting)

### IV. New Drugs to Market

#### a. Drug Reviews

Brand name (generic)	FDA Approval Date	Market/Launch Date
Abilify MyCite <sup>®</sup> ( aripiprazole with ingestible sensor ) aka Proteus ingestible sensor ( aripiprazole ) New Formulation	11/13/2018	11/13/2018
Actemra <sup>®</sup> Pre-filled Pen (ACTPen) ( tocilizumab sq soln auto-injector 162 mg/0.9 ml ) New Formulation	11/26/2018	12/17/2018
Aemcolo <sup>™</sup> ( rifamycin controlled-release ) New Molecular Entity	11/16/2018	12/19/2018
AndexXa <sup>®</sup> 200mg ( coagulation factor Xa [recombinant], inactivated-zhzo ) New Formulation	1/3/2019	1/14/2019
Bryhali <sup>™</sup> 0.01% ( halobetasol ) New Formulation	11/6/2018	11/13/2018
Cequa <sup>™</sup> ( cyclosporine ) New Formulation	8/14/2018	12/4/2018

## Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
Dsuvia <sup>TM</sup> ( sufentanil ) New Formulation	11/2/2018	11/28/2018
DAURISMO <sup>TM</sup> ( glasdegib ) New Molecular Entity	11/21/2018	11/28/2018
Elzonris <sup>TM</sup> ( tagraxofusp ) New Biologic	12/21/2018	1/28/2019
Firdapse <sup>®</sup> ( amifampridine phosphate ) New Molecular Entity	11/28/2018	12/20/2018
Gamastan <sup>®</sup> ( immune globulin [human] ) New Formulation	9/4/2018	9/4/2018
Gamifant <sup>®</sup> ( emapalumab-lzsg 10mg/2ml emapalumab-lzsg 50mg/10ml ) New Biologic	11/20/2018	12/27/2018
Khapzory <sup>TM</sup> ( levoleucovorin ) New formulation	10/9/2018	11/26/2018
Krintafel <sup>TM</sup> ( tafenoquine ) New Molecular Entity	7/20/2018	1/2/2019
Mulpleta <sup>®</sup> ( lusutrombopag ) New Molecular Entity	7/31/2018	8/22/2018
Nuzyra <sup>TM</sup> ( omadacycline ) New Molecular Entity	10/3/2018	12/11/2018
Promacta <sup>®</sup> ( eltrombopag ) New Formulation	8/24/2015	12/28/2018
Retavase <sup>®</sup> ( reteplase (18.1 mg) kit ) New Formulation	1/9/2018	12/19/2018



## Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
Revcovi™ ( elapegademase-ivlr ) New Biologic	10/5/2018	11/14/2018
Seysara™ ( sarecycline ) New Molecular Entity	10/1/2018	12/24/2018
Tolsura™ ( itraconazole ) New Formulation	12/11/2018	12/11/2018
Udenyca™ ( pegfilgrastim-cbqv ) Biosimilar of Neulasta	11/2/2018	11/30/2018
Ultomiris™ ( ravulizumab-cwyz ) New Molecular Entity	12/21/2018	12/24/2018
Vitrakvi® ( larotrectinib ) New Molecular Entity	11/26/2018	11/28/2018
XOSPATA® ( gilteritinib ) New Molecular Entity	11/28/2018	11/30/2018
Yupelri™ ( revefenacin ) New Molecular Entity	11/8/2018	11/15/2018
Yutiq ( fluocinolone acetonide ) New Formulation	10/12/2018	12/10/2018

### V. Adjournment

#### a. Future Meeting Dates

May 20, 2019

August 26, 2019

November 25, 2019

<https://www.wellcare.com/Kentucky/Providers/Medicaid/Pharmacy/Pharmacy-and-Therapeutics-Advisory-Forum>